Sara Pellegrino | Senior Vice President of Investor Relations and Corporate Communications |
Frederick Vogt | Interim President and Chief Executive Officer |
Jean-Marc Bellemin | Chief Financial Officer |
Igor Bilinsky | Chief Operating Officer |
James Ziegler | Executive Vice President, Commercial |
Friedrich Finckenstein | Chief Medical Officer |
Madan Jagasia | Executive Vice President, Medical Affairs |
Michael Yee | Jefferies |
Tyler Van Buren | Cowen |
Colleen Kusy | R.W. Baird |
Mark Breidenbach | Oppenheimer |
James Gin | Wells Fargo |
Kelsey Goodwin | Guggenheim |
Welcome to the Iovance Biotherapeutics Third Quarter and Year to-date 2022 Financial Results and Corporate Update Conference Call. My name is Andrew, and I will be your operator for today’s call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. [Operator Instructions] Please note that this conference is being recorded.